Delving into the Latest Updates on Biogen-Idec Pharmaceuticals, Inc. with Synapse

概览

疾病领域	数量

血液及淋巴系统疾病	1
免疫系统疾病	1
肿瘤	1

排名前五的药物类型	数量

单克隆抗体	1

排名前五的靶点	数量

CD80(分化群80)	1

关联

1

项与 Biogen-Idec Pharmaceuticals, Inc. 相关的药物

Galiximab

加利昔单抗

靶点

CD80

作用机制

CD80抑制剂 [+1]

在研机构

Biogen-Idec Pharmaceuticals, Inc. [+1]

原研机构

Biogen, Inc.

在研适应症

B细胞淋巴瘤

非在研适应症

银屑病 [+1]

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

100 项与 Biogen-Idec Pharmaceuticals, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Biogen-Idec Pharmaceuticals, Inc. 相关的专利（医药）

登录后查看更多信息

1

项与 Biogen-Idec Pharmaceuticals, Inc. 相关的文献（医药）

2009-06-01·Current Medical Research and Opinion4区 · 医学

Absenteeism and health-benefit costs among employees with MS

4区 · 医学

Article

作者: Melkonian, Arthur K. ; Kleinman, Nathan L. ; Brook, Richard A. ; Rajagopalan, Krithika

OBJECTIVEThe purpose of this analysis was to assess the differences in lost time and health-benefit costs (HBCs) among employees treated with disease modifying treatments (DMTs) for multiple sclerosis (MS).STUDY DESIGNEmployees with an MS diagnostic code (ICD-9 340.xx) and a DMT prescription claim (1/1/2001-6/30/2007) were identified from the HCMS Research Reference Database and assigned to DMT cohorts. The first prescription for the DMT was used as each person's index date. One-year outcomes included HBCs and absenteeism (lost time, comprising sick leave [SL], short- and long-term disability [STD/LTD], and workers' compensation).METHODSDemographics were compared using t-tests for continuous variables and chi-square tests for discrete variables. Two-part multivariate regression modeling (logistic regression combined with generalized linear regression) was used to determine annual HBCs and absenteeism for each cohort controlling for age, gender, job-related variables, and Charlson Comorbidity Score. All cost variables were inflated to US$2007.RESULTSAnnual ranges among the DMTs were: HBCs $17,953-26,970 and absenteeism 7.33-20.67 days. Compared with glatiramer acetate ('C'), IFN-beta1a IM ('A') users had lower SL ($445, p = 0.0469) and STD ($969, p = 0.0164) costs; and IFN-beta1b ('B') users had lower medical costs ($2143, p = 0.0091). In addition, those treated with 'A' had 4.2 fewer SL days (p = 0.0101) compared with those treated with 'C'.CONCLUSIONSPatients treated with 'A' reported significantly lower SL costs, SL days, and STD costs than patients treated with 'C', suggestive of greater real world benefits with 'A'. Despite small sample sizes and the retrospective nature, the study provides interesting insights into the use of DMTs in MS. The study also revealed important areas of future research, specifically the need for development of methods to determine which MS patient groups respond best to which DMT treatments.

100 项与 Biogen-Idec Pharmaceuticals, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Biogen-Idec Pharmaceuticals, Inc. 相关的转化医学

登录后查看更多信息